NCT05856383

Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC

Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in the Treatment of Advanced Breast Cancer

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 100 (estimated)
• Sponsor: Zhejiang Cancer Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, no interventional, single arm cohort study, which aims to study the efficacy and safety of inetetamab combined with pyrotinib and vinorelbine in the Treatment of HER2 positive advanced breast cancer in the real world. The study will be conducted by signing an informed consent form for study enrollment, collecting patient case information, and conducting observation and follow-up.

Detailed description

This is a prospective, no interventional, single arm cohort study, which aims to study the efficacy and safety of inetetamab combined with pyrotinib and vinorelbine in the Treatment of HER2 positive advanced breast cancer in the real world. The study will be conducted by signing an informed consent form for study enrollment, collecting patient case information, and conducting observation and follow-up.The research process is divided into screening period, treatment period, and survival and follow-up periods.

Conditions

• HER2-positive Advanced Breast Cancer

Interventions

Type	Name	Description
DRUG	Inetetamab Combined With Pyrotinib and Vinorelbine	Inetetamab Combined With Pyrotinib and Vinorelbine

Timeline

• Start date: 2022-03-16
• Primary completion: 2027-12-31
• Completion: 2027-12-31
• First posted: 2023-05-12
• Last updated: 2023-05-12

Locations

1 site across 1 country: China